Getting the timing right: when to consider a GLP-1 receptor agonist in type 2 diabetes
Join us for a live webinar in which Dr Amar Puttanna, a Consultant Diabetologist based in Sutton Coldfield, will look at the burden of type 2 diabetes, and the impact of the updated ADA/EASD guidance1 on the chronology of initiating GLP-receptor agonists in this condition.
Dr Puttanna will discuss clinical trial data for a GLP-1 receptor agonist versus basal insulin and suggest the right time for initiating GLP-1 receptor agonists. After the presentation, join Dr Puttanna for a live Q&A session.
Amar Puttanna is a Diabetes and Endocrine Consultant in the West Midlands. He is particularly interested in education, having won teaching awards from the University of Birmingham and the Royal College of Physicians of Edinburgh and currently sits on the MRCP Part 1 examining board.
Dr Puttana contributes to writing guidelines and patient information for older individuals, including those published by the Joint British Diabetes Societies and TREND-UK, as well as local guidelines. He has also served on a NICE scoping board as diabetes specialist with interest in cardiovascular disease and sits on the editorial board for the British Journal of Cardiology. His interests are in cardiovascular disease, diabetes management in older adults and cognitive impairment.